- Home
- CIVB vs FDMT Comparison
CIVB vs FDMT Comparison
Compare CIVB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIVB | FDMT |
|---|---|---|
| Founded | 1884 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.3M | 449.6M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CIVB | FDMT |
|---|---|---|
| Price | $25.56 | $9.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $26.60 | ★ $31.71 |
| AVG Volume (30 Days) | 51.4K | ★ 566.8K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 31.34 | 18.79 |
| EPS | ★ 0.72 | N/A |
| Revenue | $19,023,000.00 | ★ $85,209,000.00 |
| Revenue This Year | $14.88 | N/A |
| Revenue Next Year | $5.99 | $70.28 |
| P/E Ratio | $35.50 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $18.95 | $3.68 |
| 52 Week High | $26.15 | $12.34 |
Technical Indicators
Market Signals| Indicator | CIVB | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 55.03 |
| Support Level | $21.39 | $9.71 |
| Resistance Level | $25.99 | $9.78 |
| Average True Range (ATR) | 0.68 | 0.61 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 70.21 | 60.32 |
Price Performance
Historical ComparisonAbout CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).